Multiple Myeloma
Featured Articles
(Karyopharm Therapeutics) Oct 5, 2018 - Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority Review its New Drug Application (NDA) seeking accelerated approval for selinexor, its first in class, oral SINE compound, as...
Read Article
(Markets Insider) Oct 1, 2018 - Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to expand the Prescribing Information for KYPROLIS® (carfilzomib) to include a once-weekly dosing option in combination with dexamethasone (once-weekly Kd70) for patients with...
Read Article
Latest Articles
October 10, 2018
October 08, 2018
October 03, 2018
October 01, 2018
October 01, 2018
September 24, 2018
September 24, 2018
September 19, 2018
View More
News Commentary
Editor Image
14 Mar, 2018 | by Thomas Marsland, MD
Drug pricing and the costs of medications is clearly an ongoing problem. But as...
View Comment
Editor Image
07 Mar, 2018 | by Jeff Patton, M.D.
There are certainly some perverse incentives in medicine but there is a...
View Comment
View More
OBR Green
There are no Multiple Myeloma OBR Green articles.
OBR Blog
There are no Multiple Myeloma blog entries.